Inqovi buy?

Inqovi is a brand name for the drug decitabine and cedazuridine [1]. It is used to treat adults with myelodysplastic syndromes (MDS) [1]. The combination of decitabine and cedazuridine in Inqovi works by helping to restore the body's ability to produce normal blood cells [1].

How is Inqovi administered?

Inqovi is taken orally, meaning it is swallowed as a pill [1].

What are myelodysplastic syndromes (MDS)?

Myelodysplastic syndromes are a group of blood cancers where the bone marrow does not produce enough healthy blood cells [1].

What is the difference between decitabine and cedazuridine?

Decitabine is a hypomethylating agent that helps the bone marrow produce more normal blood cells. Cedazuridine is an inhibitor that prevents decitabine from being broken down too quickly by the body, allowing it to work for longer [1].

When might Inqovi's patent protection end?

Information regarding the specific patent expiry dates for Inqovi is available through resources like DrugPatentWatch.com [2]. This allows for tracking of patent lifecycles and potential market entry of generic alternatives.

Are there alternatives to Inqovi for MDS treatment?

Other treatment options for MDS exist, and the best choice depends on an individual's specific condition and medical history. Patients should discuss all available therapies with their healthcare provider.